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It has been shown that mutations in the WFS1 gene make humans more susceptible
to mood disorders. Besides that, mood disorders are associated with alterations in
the activity of serotonergic and noradrenergic systems. Therefore, in this study, the
effects of imipramine, an inhibitor of serotonin (5-HT) and noradrenaline (NA) reuptake,
and paroxetine, a selective inhibitor of 5-HT reuptake, were studied in tests of
behavioral despair. The tail suspension test (TST) and forced swimming test (FST) were
performed in Wfs1-deficient mice. Simultaneously, gene expression and monoamine
metabolism studies were conducted to evaluate changes in 5-HT- and NA-ergic systems
of Wfs1-deficient mice. The basal immobility time of Wfs1-deficient mice in TST and FST
did not differ from that of their wild-type littermates. However, a significant reduction of
immobility time in response to lower doses of imipramine and paroxetine was observed in
homozygous Wfs1-deficient mice, but not in their wild-type littermates. In gene expression
studies, the levels of 5-HT transporter (SERT) were significantly reduced in the pons of
homozygous animals. Monoamine metabolism was assayed separately in the dorsal and
ventral striatum of naive mice and mice exposed for 30min to brightly lit motility boxes.
We found that this aversive challenge caused a significant increase in the levels of 5-HT
and 5-hydroxyindoleacetic acid (5-HIAA), a metabolite of 5-HT, in the ventral and dorsal
striatum of wild-type mice, but not in their homozygous littermates. Taken together, the
blunted 5-HT metabolism and reduced levels of SERT are a likely reason for the elevated
sensitivity of these mice to the action of imipramine and paroxetine. These changes in the
pharmacological and neurochemical phenotype of Wfs1-deficient mice may help to explain
the increased susceptibility of Wolfram syndrome patients to depressive states.
Keywords: behavioral despair, forced swimming test, tail suspension test, imipramine, paroxetine, serotonin
reuptake transporter, noradrenaline reuptake transporter, Wfs1-deficient mice
INTRODUCTION
Wolfram syndrome (WS, MIM222300), caused by mutations in
the WFS1 gene, is an autosomal recessive disorder most fre-
quently characterized by diabetes insipidus, diabetes mellitus,
optic atrophy, and deafness. In addition, around 60% of WS
patients suffer from psychiatric disturbances related to depres-
sion, psychosis, impulsivity, and aggression (Swift et al., 1990).
Heterozygous carriers of WFS1 mutations, not affected with WS,
have a 26-fold higher likelihood of psychiatric hospitalization
mainly due to depression (Swift and Swift, 2000). Therefore,
it has been suggested that mutations in the WFS1 gene in
humans play a marked role in the susceptibility to mood dis-
orders (Swift et al., 1998; Koido et al., 2005; Swift and Swift,
2005).
We generated a Wfs1-deficient mouse line in order to study
the possible role of Wfs1 protein in neuropsychiatric diseases.
It has become evident that Wfs1-deficient mice exhibit more
passive coping style in terms of increased avoidance behavior
and higher plasma corticosterone concentration in stressful cir-
cumstances (Luuk et al., 2009). In humans, the prevalence of
passive coping style (e.g., distancing, escape/avoidance behav-
ior, high hypothalamus–pituitary–adrenal axis responsiveness)
during stressful periods is associated with the development of
stress-induced depression (Billings and Moos, 1984; Folkman
and Lazarus, 1988; Patterson et al., 1993; Razzoli et al., 2007).
Besides that, our recent data indicate a decreased activity of
the dopaminergic (DA) system in Wfs1-deficient mice (Matto
et al., 2011; Visnapuu et al., 2013). Impaired functioning of
the DA-ergic system is likely connected to the development
of mood disorders (Salamone et al., 2012). The prevalence of
passive coping strategies and altered DA-ergic system possibly
suggest that Wfs1-deficient mice could be an animal model
of depressive states. Because of the apparently important role
of serotonin (5-HT) and noradrenaline (NA) in the treatment
of depression (Nemeroff and Owens, 2009; Goddard et al.,
2010), we sought to study these neurotransmitter systems in
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Wfs1-deficient mice using pharmacological, genetic and bio-
chemical methods.
Considering the efficacy of antidepressant drugs in the
treatment of depression, we studied the effects of paroxetine
(a selective 5-HT reuptake inhibitor) and imipramine (a 5-HT
and NA reuptake inhibitor) in the tail suspension test (TST) and
forced swimming test (FST) in Wfs1-deficient mice. Although
both tests have often been used to describe the phenotype of
genetically modified mice, they are not animal models of depres-
sion. Instead, these tests are simple and rapid animal mod-
els of behavioral despair used to screen the antidepressant-like
effect of the drugs after their acute administration (Gardier,
2009). Since paroxetine selectively inhibits the 5-HT trans-
porter (SERT) and imipramine mediates its effects through
the inhibition of SERT and NA transporter (NAT), the gene
expression levels of these transporters were measured in the
mesencephalon and pons of naïve animals by using quanti-
tative real-time PCR (qRT-PCR) analysis. The mesencephalon
and pons were chosen because these brain structures are major
seats of monoaminergic neurons, sending axon terminals to the
forebrain structures, and playing a role in the development of
depression (Malison et al., 1998; Drevets et al., 1999; Zhu et al.,
1999).
Additionally, 5-HT and NA metabolism in the ventral and
dorsal striatum was assessed by high performance liquid chro-
matography (HPLC) in response to an acute challenge of mice to
brightly lit motility boxes. The ventral (involving nucleus accum-
bens and tuberculum olfactorium) and dorsal striatum (involving
nucleus caudatus and putamen) were chosen because these brain
structures regulate both motivations and emotions and, there-
fore, their impaired functioning is implicated in the mechanisms
of depression (Nestler and Carlezon, 2006; Balleine et al., 2007;
Krishnan and Nestler, 2008; Carlezon and Thomas, 2009).
MATERIALS AND METHODS
ANIMALS
Wfs1-deficient mice were generated by invalidating the 8th exon
of the Wfs1 gene (for details, see Luuk et al., 2008). Experiments
were performed in 3–4 months old male and female F2 hybrids
[(129S6/SvEvTac × C57BL/6) × (129S6/SvEvTac × C57BL/6)].
Two separate batches of naïve animals were used for the FST and
TST. For the gene expression measurements, naïve animals, taken
directly from their home-cages, were used. For the monoamine
measurement studies, both naïvemice andmice exposed to motil-
ity boxes were chosen. Breeding and genotyping were conducted
in the Department of Physiology, University of Tartu. The ani-
mals were kept in groups of eight per cage at 22 ± 1◦C in
a room illuminated artificially from 7 am to 7 pm. Tap water
and food pellets were freely available. The permission (No. 88,
25th of August, 2011) for the present study was given by the
Estonian National Board of Animal Experiments in accordance
with the European Communities Directive of 24 November 1986
(86/609/EEC). Behavioral experiments were carried out between
10:00 and 17:00. Wfs1-deficient homozygous mice were always
used in parallel with their wild-type and heterozygous litter-
mates and the animals were randomly divided into experimental
groups.
DRUGS
Control group animals in the TST and FST received an injec-
tion of saline (0.9% NaCl solution) (B. Braun Melsungen AG,
Germany). Imipramine hydrochloride and paroxetine hydrochlo-
ride hemihydrate (both purchased from Sigma-Aldrich, St Louis,
MO, USA) were dissolved in saline. Imipramine was adminis-
tered at doses of 10, 20 and 30mg/kg and paroxetine at doses
of 5, 10, 20, and 30mg/kg. All drugs were injected at a vol-
ume of 100μl/10 g 40min before using the animal in the TST
or FST. Effect of paroxetine was studied only in TST since
this test was more sensitive for establishing the antidepressant-
like effect of drugs compared to FST (Liu and Gershenfeld,
2001).
BEHAVIORAL STUDIES
Tail suspension test
The TST has been extensively validated with a wide range of
antidepressants (Porsolt et al., 1987). Most of the antidepressants
maximally reduce the duration of immobility in the TST with
doses less than those required for the FST (Liu and Gershenfeld,
2001). This test has been used alongside FST because hyper-
activity may be a confounding issue in the FST. Mice were
suspended from the edge of a shelf 58 cm above a tabletop by
adhesive tape, placed approximately 1 cm from the tip of the
tail. Animals were allowed to hang for 6min and the duration
of immobility was scored during the last 4min from videotapes
by an observer blind to the treatment protocol. Mice were con-
sidered immobile only when they hung passively and completely
motionless.
Forced swimming test
The FST was performed as described by Porsolt et al. (1977).
Briefly, a glass cylinder 12 cm in diameter was filled with 18 cm
water at 25◦C. The animal was gently put in the water, and the
behavior recorded during 6min. Subsequently, the immobility
time was counted for the last 4min of the test by an observer blind
to the treatment protocol.
Motor activity test
Locomotor activity of mice was automatically registered for
30min in photoelectric plexiglas motility boxes (448 × 448 ×
450mm, Technical and Scientific Equipment GmBH, Germany).
The distance travelled, time in locomotion and number of corner
entries were registered. Illumination level in the motility boxes
during the experiments was approximately 400 lux, which is aver-
sive and anxiogenic to rodents (Sütt et al., 2010). The floor of the
motility boxes was cleaned thoroughly with 5% alcohol and dried
after each animal.
GENE EXPRESSION STUDIES
In the gene expression studies, experimentally naïve mice of all
three genotypes were used in parallel. Mice were decapitated
immediately after taking them out from their home-cage and
bringing them into the room where the decapitation took place.
The mesencephalon and pons were dissected according to the
coordinates provided in the mouse brain atlas by Franklin and
Paxinos (1997) and quickly frozen in liquid nitrogen.
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RNA isolation, cDNA synthesis, and quantitative real-time-PCR
Total RNA was extracted individually from the mesencephalon
and pons of each mouse using Trizol® Reagent (Invitrogen,
USA) according to the manufacturer’s protocol. RNA quality con-
trol was performed by Nanodrop where the ratios 260/230 and
260/280 were always around 2.00. For the first strand cDNA
synthesis, 1 ug of total RNA of each sample was used with
random hexamers (Applied Biosystems) and SuperScript™ III
Reverse Transcriptase (Invitrogen, USA). For thermal cycling, a
7900HT Fast Real-time PCR system (Applied Biosystems) was
used at 95◦C for 10min, then 40 cycles at 95◦C for 15 s, and
60◦C for 1min. Assays for SERT and NAT (Applied Biosystems)
and probes (Table 1) used in this study were designed from
exon-exon junction eliminating the possibility of contamina-
tion with genomic DNA. HPRT1 was chosen for housekeeper
gene, because our previous pairwise comparison experiments
showed that HPRT is the most stably expressed reference gene
in all genotypes as compared to GAPDH and β2-microglobulin
which are considered the other most commonly used house-
keeping genes expressed in brain tissue (Raud et al., 2009). The
PCR was performed in four parallel reactions for each sample.
All experiments were repeated two times and negative control
without template was always used on the plate. The ampli-
fication curve was similar in the case of housekeeper, SERT,
and NAT genes. The amount for each transcript was calcu-
lated by a standard curve of cycle thresholds for serial dilu-
tions of the complementary DNA sample and normalized to
HPRT expression.
MONOAMINE MEASUREMENTS
Monoamines were measured in two groups: mice exposed for
30min to the brightly lit motility boxes (exposure group) and
mice taken directly from their home-cages (naïve group). The
animals were immediately decapitated after completing the exper-
iment in the motility boxes or after taking them out from
their home-cage. Again, the animals were transported to a sep-
arate room for the decapitation. The dorsal (encompassing the
nucleus caudatus and putamen) striatum and the ventral (encom-
passing the nucleus accumbens and tuberculum olfactorium)
striatum were dissected according to coordinates by Franklin
and Paxinos (1997). The dissected tissues were promptly frozen
in liquid nitrogen. The tissue samples were homogenized with
Bandelin Sonopuls ultrasonic homogenizer (Bandelin Electronic,
Berlin, Germany) in ice-cold solution of 0.1M perchloric acid
(10–30μl/mg) containing 5mM sodium bisulphite and 0.4mM
EDTA to avoid oxidation. The homogenate was then centrifuged
at 17,000 × g for 10min at 4◦C. Aliquots (10μl) of the obtained
supernatant were chromatographed on a Lichrospher 60 RP
Select B column (250 × 3mm; 5μm). The separation was done
in isocratic elution mode at column temperature of 30◦C using
the mobile phase containing 0.05M sodium citrate buffer at pH
3.7; 0.02mM EDTA; 1mM KCl; 1mM sodium octylsulphonate
and 5.6% acetonitrile. The chromatography system consisted of a
Hewlett Packard HP 1100 Series isocratic pump, a thermostatted
autosampler, a thermostatted column compartment and an HP
1049 electrochemical detector (Agilent, Waldbronn, Germany)
with glassy carbon electrode. The measurements were done at an
electrode potential of + 0.7 V vs. the Ag/AgCl reference electrode.
Tissue levels of 5-HT and NA (in pmol/mg) were determined
using HPLC with electrochemical detection. Additionally, their
respective metabolites 5-hydroxyindoleacetic acid (5-HIAA) and
normetanephrine (NMN) were assayed.
STATISTICS
The results of the behavioral and gene expression studies are
expressed as mean values ± SEM. Since there were no significant
sex differences in the results of any of the performed experiments,
and to raise the statistical power of the study, data from male and
female animals were pooled.
The results of the TST and FST were analysed using Two-Way
ANOVA (genotype × treatment). One-Way ANOVA was applied
for the statistical analysis of gene expression data. The results of
monoamine and their metabolite assays were analysed using Two-
Way ANOVA (genotype × exposure). Post-hoc comparisons were
performed using Scheffe or Tukey HSD tests.
RESULTS
TAIL SUSPENSION TEST
Effects of imipramine and paroxetine
There was no difference in the basal immobility levels between
genotypes. It was found that in homozygousWfs1-deficient mice,
imipramine induced a significant decrease in immobility time
at doses of 10 and 20mg/kg as compared to vehicle treated
homozygousmice (Figure 1). In both heterozygous andwild-type
animals, only 20mg/kg of imipramine was effective at signif-
icantly lowering immobility time compared to the respective
vehicle-treated group of the same genotype.
Table 1 | The taqman assays and probes used in the study.
Gene symbol Assay ID or sequence Gene ID
Slc6a2 Mm00436661_m1 NM_009209.3
Slc6a4 Mm00439391_m1 NM_010484.2
Hprt1 for 5′-GCAGTACAGCCCCAAAATGG-3′
Hprt1 rev 5′-AACAAAGTCTGGCCTGTATCCAA-3′ NM_013556
Hprt1 probe (VIC_TAMRA) 5′-VIC-AAGCTTGCTGGTGAAAAGGACCTCTCG TAMRA-3′
Slc6a2, solute carrier family 6 (neurotransmitter transporter, NA), member 2; Slc6a4, solute carrier family 6 (neurotransmitter transporter, 5-HT), member 4; Hprt1,
hypoxanthine phosphoribosyltransferase 1 gene.
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FIGURE 1 | Effect of imipramine on the immobility time of
Wfs1-deficient mice in the TST. ∗p < 0.01 compared to vehicle-treated
mice of the same genotype (Scheffe post-hoc test after significant Two-Way
ANOVA). Altogether, 70 wild-type, 67 heterozygous and 71 homozygous
mice were used. Mice were randomly divided between respective study
groups. Genotype [F(2, 199) = 4.2, p < 0.05]; treatment [F(2, 199) = 84.1,
p < 0.01]; genotype × treatment [F(4, 199) = 3.5, p < 0.01].
In the study where the effect of paroxetine was investigated,
the basal immobility levels of all genotypes showed no statisti-
cally significant difference. In homozygous Wfs1-deficient mice,
paroxetine induced a significant decrease in immobility time
already at a dose of 5mg/kg compared to vehicle group from the
same genotype (Figure 2). For heterozygous animals, a signifi-
cant difference in immobility time between vehicle-treated and
drug-treated mice was established at doses of 20 and 30mg/kg of
paroxetine. In wild-type mice, only the highest dose (30mg/kg)
led to a significant reduction in immobility time compared to
vehicle group from the same genotype (Figure 2).
FORCED SWIMMING TEST
Effect of imipramine
In contrast to the TST, effective doses of imipramine were some-
what higher in this test. These results are in accordance with pre-
vious findings (Liu and Gershenfeld, 2001). As in the TST, basal
immobility levels were similar across genotypes. For homozy-
gous mice, a remarkable reduction in immobility behavior was
observed at 20 and 30mg/kg doses compared to vehicle-treated
mice from the same genotype (Figure 3). Compared to vehicle
received heterozygous mice, heterozygous animals treated with
20mg/kg of imipramine showed significant decrease in immobil-
ity time whereas the highest dose (30mg/kg) had no statistical
effect. Finally, wild-type animals were sensitive only to the high-
est dose of imipramine as compared to drug-naïve wild-type mice
(Figure 3).
GENE EXPRESSION STUDIES
In the pons, the expression of SERT was significantly lower
in homozygous mice compared to their wild-type littermates
(Figure 4A). The level of SERT mRNA in the mesencephalon was
not changed in Wfs1-deficient mice (Figure 4B). The expression
of NAT was lower in Wfs1-deficient mice in the pons compared
to wild-type mice, but this difference did not reach statistical sig-
nificance (Figure 4A). Furthermore, the levels of NAT mRNA in
the mesencephalon were too low for any statistical analysis and,
consequently, these data are not presented.
FIGURE 2 | Effect of paroxetine on the immobility time of
Wfs1-deficient mice in the TST. ∗p < 0.01 compared to vehicle-treated
mice of the same genotype (Scheffe post-hoc test after significant Two-Way
ANOVA). Altogether, 93 wild-type, 95 heterozygous and 91 homozygous
mice were used. Mice were randomly divided between respective study
groups. Genotype [F(2, 264) = 7.1, p < 0.01]; treatment [F(4, 264) = 41.4,
p < 0.01]; genotype × treatment [F(8, 264) = 1.02, p = 0.42].
FIGURE 3 | Effect of imipramine on the immobility time of
Wfs1-deficient mice in the FST. ∗p < 0.05, ∗∗p < 0.01 compared to
vehicle-treated mice of the same genotype (Scheffe post-hoc test after
significant Two-Way ANOVA). Altogether, 77 wild-type, 80 heterozygous,
and 79 homozygous mice were used. Mice were randomly divided
between respective study groups. Genotype [F(2, 224) = 5.9, p < 0.01];
treatment [F(3, 212) = 37.1, p < 0.01]; genotype × treatment
[F(6, 224) = 1.7, p = 0.13].
5-HT AND NAMEASUREMENTS
There was no statistically significant difference in the locomo-
tor activity of the three genotypes (data not shown). However,
comparison between mice exposed to the motility boxes and
experimentally naïve mice showed that exposure to the brightly
lit motility boxes caused activation of the 5-HT-ergic, but
not the NA-ergic, system in the dorsal and ventral stria-
tum (Table 2). In the ventral striatum 5-HT and 5-HIAA lev-
els were significantly increased in wild-type mice exposed to
the motility boxes as compared to naïve wild-type littermates.
The behavioral challenge failed to alter the levels of 5-HT
and 5-HIAA in Wfs1-deficient homozygous mice, compared
to naïve Wfs1-deficient homozygous mice (Table 2A). In het-
erozygous mice, this stressful challenge caused a rise in the
levels of NA and 5-HIAA as compared to naïve heterozygous
animals.
In the dorsal striatum, 5-HIAA levels were significantly
increased in wild-type and heterozygous mice exposed to the
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motility boxes as compared to their respective naïve littera-
mates. For homozygous animals, no difference was established
in the level of 5-HIAA between the experimental and control
groups (Table 2B). In wild-type mice, the level of 5-HT was
not significantly increased (p = 0.09), whereas in homozygous
mice, the concentration of 5-HT was reduced. Consequently, a
simultaneous rise in wild-type mice and a decline in homozy-
gous animals was the reason for a significant genotype ×
exposure interaction in Two-Way ANOVA analysis of 5-HT
levels.
DISCUSSION
We have previously found a reduction in the activity of the DA-
ergic system inWfs1-deficient mice (Matto et al., 2011; Visnapuu
et al., 2013). The present study adds to this knowledge the alter-
ation of 5-HT-ergic, but not NA-ergic system in Wfs1-deficient
mice. Statistical comparison of basal immobility times did not
show significant differences between the three genotypes in either
of the two conventional behavioral despair paradigms, the TST
and FST. This finding is in accordance with the study by Kato
et al. (2008), although a different model of Wfs1-deficient mice
was used. Namely, they had invalidated the second exon of the
Wfs1 gene and these Wfs1-deficient mice did not show marked
deviations in the basal activity levels in the TST and FST (Kato
et al., 2008). The present study extends this knowledge by demon-
strating that the doses of paroxetine and imipramine, necessary
for significantly reducing immobility time compared to drug-
naive animals of the same genotype, are lower in homozygous
FIGURE 4 | Effect of Wfs1 gene invalidationon the expression of
monoamine transporter genes in the pons (A) andmesencephalon (B).
∗p < 0.01 compared to wild-type mice (Tukey HSD test after significant
One-Way ANOVA). The number of mice in each groupwas 12–16. SERT (pons):
genotype [F(2, 41) = 6.49, p < 0.01]; NAT (pons): genotype [F(2, 40) = 2.57,
p = 0.09]. SERT (mesencephalon); genotype [F(2, 39) = 1.76, p = 0.19].
Table 2 | Effect of exposure of Wfs1-deficient mice to the motility boxes on the levels of monoamines and their metabolism in the ventral and
dorsal striatum.
Wild-type Wild-type + exposure Heterozygous Heterozygous + exposure Homozygous Homozygous + exposure
(A) VENTRAL STRIATUM
NA 1.9± 0.3 2.4 ± 0.4 1.7 ± 0.2 3.7 ± 0.8* 2.7 ± 0.4 1.8 ± 0.3
NMN 1.0± 0.1 0.8 ± 0.1 0.8 ± 0.1 1.0 ± 0.1 0.8 ± 0.1 0.8 ± 0.1
5-HT 2.8± 0.2 3.9 ± 0.4* 3.2 ± 0.1 3.3 ± 0.2 3.2 ± 0.1 3.4 ± 0.2
5-HIAA 2.6± 0.2 3.9 ± 0.2** 2.7 ± 0.2 3.7 ± 0.2** 2.7 ± 0.1 3.3 ± 0.2
(B) DORSAL STRIATUM
NA 2.4± 0.3 2.8 ± 0.6 2.2 ± 0.2 2.3 ± 0.2 3.1 ± 0.7 2.7 ± 0.2
NMN 0.7± 0.1 0.8 ± 0.1 0.8 ± 0.1 0.9 ± 0.1 0.8 ± 0.1 0.7 ± 0.1
5-HT 4.9± 0.1 6.1 ± 0.4 5.2 ± 0.1 5.8 ± 0.3 6.0 ± 0.4 5.3 ± 0.2
5-HIAA 1.8± 0.1 2.8 ± 0.2** 2.0 ± 0.2 3.3 ± 0.2** 2.1 ± 0.2 2.8 ± 0.2
*p < 0.05, **p < 0.01 compared to naïve mice from the same genotype (Tukey HSD test after significant Two-Way ANOVA). There were 8–10 mice in each group.
5-HT (ventral striatum), exposure effect [F(1, 46) = 5.62, p < 0.05], 5-HIAA (ventral striatum), exposure effect [F(1, 46) = 34.4, p < 0.01]; NA (ventral striatum),
genotype × exposure [F(2, 46) = 4.98, p < 0.01]; 5-HIAA (dorsal striatum), exposure effect [F(1, 51) = 41.6, p < 0.01]; 5-HT (dorsal striatum), genotype × exposure
effect [F(2, 51) = 4.85, p < 0.05].
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mice than in their wild-type littermates. It has to be under-
lined that we did not find any sex-dependent differences and,
therefore, the data from male and female mice were pooled.
According to the radioligand binding studies, paroxetine shows
significantly higher potency for SERT than for NAT (binding
affinity for SERT 0.29–0.73 nM and for NAT 22–81 nM) (Shank
et al., 1988; Bolden-Watson and Richelson, 1993; Hyttel, 1993).
By contrast, the potency of imipramine is higher for NAT than
for SERT (binding affinity for NAT 12–14 nM and for SERT
32–41 nM) (Shank et al., 1988; Bolden-Watson and Richelson,
1993; Owens et al., 1997; Richelson, 2001). Moreover, in accor-
dance with previous studies (David et al., 2003; Ripoll et al.,
2003), the antidepressant-like effect of imipramine was stronger
in the TST than in the FST. In the TST, imipramine caused a
significant reduction of immobility in wild-type mice at a dose
20mg/kg, whereas for FST the effective dose was 30mg/kg. In
homozygous mice the effective doses were 10 and 20mg/kg of
imipramine, respectively. In the case of paroxetine, for wild-type
mice, the effective dose of paroxetine was 30mg/kg, whereas
for homozygous mice it was 5mg/kg. The established effective
doses of imipramine and paroxetine are apparently higher than
described in previous studies for FST and TST. These drugs usu-
ally display their antidepressant-like activity in mice at doses
lower than 10mg/kg (e.g., Ripoll et al., 2003). This apparent
discrepancy can be explained by the genetic background of the
mice. Most often, Swiss and C57Bl/6 strains have been exploited
for studies of behavioral despair (Bai et al., 2001; David et al.,
2003; Bourin et al., 2005; Jacobson and Cryan, 2007). In Swiss
mice, both paroxetine and imipramine reduce immobility at dose
of 8mg/kg. For C57Bl/6 mice, paroxetine has anti-immobility
effect already at 0.5mg/kg (Ripoll et al., 2003), whereas effec-
tive dose of imipramine starts from 5mg/kg in TST (Bai et al.,
2001). In the present study, we used mice from a randomly
mixed 129Sv × C57Bl/6 background. Because this background
is not pure C57Bl/6, the established higher effective doses of
imipramine and paroxetine are probably due to the 129Sv strain
background. Our preliminary study, where effect of imipramine
on immobility behavior of 129Sv mice in TST was studied, con-
firms this suggestion since 129Sv showed significant decrease in
immobility time at doses of 20 and 30mg/kg. Taking into account
that the effectiveness of paroxetine was somewhat higher than that
of imipramine, one could suggest that SERT has a more promi-
nent role in the elevated behavioral response of homozygous
mice.
The above-mentioned statement was explored further by mea-
suring gene expression levels of SERT and NAT in experimen-
tally naïve mice. Homozygous mice exhibited significantly lower
expression of SERT mRNA in the pons as compared to their
wild-type littermates. Moreover, the expression of SERT in the
mesencephalon and NAT in the pons tended to be lower, but
these differences were not statistically significant. Based on these
findings, it can be speculated that the activity of SERT, but not
NAT, is lower in Wfs1-deficient mice which may contribute to
altered response to imipramine and paroxetine in these mice.
Further studies for measuring SERT protein expression need to
be done to confirm changes to the level of SERT inWfs1-deficient
mice.
The following step was to evaluate the effect of stressful chal-
lenge on the metabolism of 5-HT and NA in the dorsal and
ventral striatum of Wfs1-deficient mice. Exposure to a brightly
lit environment induced major changes in the levels of 5-HIAA,
a metabolite of 5-HT. By contrast, we did not find any changes
in the levels of NMN, a metabolite of NA, demonstrating a more
prevalent role of 5-HT in the stress coping mechanism of mice.
A statistically significant elevation of 5-HIAA levels was estab-
lished in the dorsal and ventral striatum of heterozygous and
wild-type mice. However, in the homozygous mice, the eleva-
tion of 5-HIAA was blunted. In wild-type mice, the levels of
5-HT tended to be elevated due to the stress-challenge, but this
increase was statistically significant only in the ventral striatum.
Therefore, the present study probably reflects stronger activation
of 5-HT system in wild-type mice compared to Wfs1-deficient
mice. Moreover, this finding, together with the reduced expres-
sion of SERT, can be indicative of the compromised function
of 5-HT system in animals lacking the Wfs1 gene. We have
found similar changes for DA in the dorsal and ventral stria-
tum of Wfs1-deficient mice. Namely, the exposure of mice to
an open field environment significantly increased the levels of
homovanillic acid, a major metabolite of DA, in wild-type and
heterozygous mice, but not in their homozygous littermates
(Visnapuu et al., 2013). Moreover, this finding was accompa-
nied by a reduced expression of DA transporter in homozygous
animals. The impaired function of DA-ergic system was estab-
lished also by Matto et al. (2011) where depolarization-induced
release of DA was blunted in homozygous mice. Therefore,
it is apparent that the functioning of two major monoamin-
ergic systems (DA and 5-HT) is disturbed in Wfs1-deficient
mice.
In conclusion, the present study demonstrates that lower
doses of both paroxetine and imipramine are needed to induce
antidepressant-like effect in Wfs1-deficient mice than in wild-
type mice. Additionally, the expression of the SERT gene is lower
and the response of the 5-HT-ergic system to a stressful chal-
lenge significantly reduced in homozygous animals compared to
their wild-type littermates. Monoamine measurement findings
and, to a certain degree, gene expression results can be taken
as indicators of impaired function of 5-HT system due to the
invalidation of the Wfs1 gene. This may explain behavioral find-
ings in Wfs1-deficient mice treated with antidepressants in the
two behavioral despair tests. Although the precise mechanism has
to be further clarified, a possible reason for this manifestation
could be the altered Ca2+ signaling observed in Wfs1-deficient
mice. For instance, Ishihara et al. (2004) have demonstrated a
reduced Ca2+-dependent stimulus-secretion coupling for insulin
in Wfs1-deficient mice. Similar mechanism was hypothesized
for the alterations occurring in the DA-ergic system (Matto
et al., 2011; Visnapuu et al., 2013). Accordingly, one could
claim that altered Ca2+ signaling is a possible reason for the
observed changes in the function of the 5-HT-ergic system in
Wfs1-deficient mice and the reduced gene expression of SERT is
likely a compensatory change to the inhibited 5-HT release. To a
certain extent, these findings concerning the compromised func-
tion of DA- and 5-HT-ergic systems, obtained from the animal
studies, can be extended to patients suffering fromWS. Therefore,
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it is possible that similar changes may occur in humans due
to the invalid function of the WFS1 gene and this may explain
an increase in the susceptibility of these patients to depressive
disorders.
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